These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 10555574)

  • 1. Toxicity of platinum(II) amino acid (N,O) complexes parallels their binding to DNA as measured in a new solid phase assay involving a fluorescent HMG1 protein construct readout.
    Ziegler CJ; Sandman KE; Liang CH; Lippard SJ
    J Biol Inorg Chem; 1999 Aug; 4(4):402-11. PubMed ID: 10555574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA binding studies with cis-dichlorobis (5(6)-non/chlorosubstituted-2-hydroxymethyl-benzimidazole) platinum(II) complexes.
    Gümüş F; Algül O
    J Inorg Biochem; 1997 Oct; 68(1):71-4. PubMed ID: 9379182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A single HMG domain in high-mobility group 1 protein binds to DNAs as small as 20 base pairs containing the major cisplatin adduct.
    Chow CS; Barnes CM; Lippard SJ
    Biochemistry; 1995 Mar; 34(9):2956-64. PubMed ID: 7893709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The binding affinity of HMG1 protein to DNA modified by cis-platin and its analogs correlates with their antitumor activity.
    Pasheva EA; Ugrinova I; Spassovska NC; Pashev IG
    Int J Biochem Cell Biol; 2002 Jan; 34(1):87-92. PubMed ID: 11733188
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Photoreactivity of platinum(II) in cisplatin-modified DNA affords specific cross-links to HMG domain proteins.
    Kane SA; Lippard SJ
    Biochemistry; 1996 Feb; 35(7):2180-8. PubMed ID: 8652559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intercalating residues determine the mode of HMG1 domains A and B binding to cisplatin-modified DNA.
    He Q; Ohndorf UM; Lippard SJ
    Biochemistry; 2000 Nov; 39(47):14426-35. PubMed ID: 11087395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Formation of large nucleoprotein complexes upon binding of the high-mobility-group (HMG) box B-domain of HMG1 protein to supercoiled DNA.
    Stros M; Reich J
    Eur J Biochem; 1998 Jan; 251(1-2):427-34. PubMed ID: 9492314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stopped-flow fluorescence studies of HMG-domain protein binding to cisplatin-modified DNA.
    Jamieson ER; Lippard SJ
    Biochemistry; 2000 Jul; 39(29):8426-38. PubMed ID: 10913248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Specificity of platinum-DNA adduct repair.
    Chaney SG; Vaisman A
    J Inorg Biochem; 1999 Oct; 77(1-2):71-81. PubMed ID: 10626357
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of DNA polymerases and high mobility group protein 1 on the carrier ligand specificity for translesion synthesis past platinum-DNA adducts.
    Vaisman A; Lim SE; Patrick SM; Copeland WC; Hinkle DC; Turchi JJ; Chaney SG
    Biochemistry; 1999 Aug; 38(34):11026-39. PubMed ID: 10460158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recognition of platinum-induced DNA damage by nuclear proteins: screening for mechanisms.
    Marples B; Adomat H; Billings PC; Farrell NP; Koch CJ; Skov KA
    Anticancer Drug Des; 1994 Oct; 9(5):389-99. PubMed ID: 7945723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cisplatin-DNA adducts inhibit ribosomal RNA synthesis by hijacking the transcription factor human upstream binding factor.
    Zhai X; Beckmann H; Jantzen HM; Essigmann JM
    Biochemistry; 1998 Nov; 37(46):16307-15. PubMed ID: 9819223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapid fluorescence-based reporter-gene assays to evaluate the cytotoxicity and antitumor drug potential of platinum complexes.
    Sandman KE; Marla SS; Zlokarnik G; Lippard SJ
    Chem Biol; 1999 Aug; 6(8):541-51. PubMed ID: 10421759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New platinum(II) complexes containing both an O,O'-chelated acetylacetonate ligand and a sulfur ligand in the platinum coordination sphere induce apoptosis in HeLa cervical carcinoma cells.
    Muscella A; Calabriso N; De Pascali SA; Urso L; Ciccarese A; Fanizzi FP; Migoni D; Marsigliante S
    Biochem Pharmacol; 2007 Jun; 74(1):28-40. PubMed ID: 17481588
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Laser-induced photo-cross-linking of cisplatin-modified DNA to HMG-domain proteins.
    Mikata Y; He Q; Lippard SJ
    Biochemistry; 2001 Jun; 40(25):7533-41. PubMed ID: 11412107
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Energetics, conformation, and recognition of DNA duplexes containing a major adduct of an anticancer azolato-bridged dinuclear Pt(II) complex.
    Mlcouskova J; Malina J; Novohradsky V; Kasparkova J; Komeda S; Brabec V
    Biochim Biophys Acta; 2012 Oct; 1820(10):1502-11. PubMed ID: 22683702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNA adducts of antitumor trans-[PtCl2 (E-imino ether)2].
    Brabec V; Vrána O; Nováková O; Kleinwächter V; Intini FP; Coluccia M; Natile G
    Nucleic Acids Res; 1996 Jan; 24(2):336-41. PubMed ID: 8628659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Basis for recognition of cisplatin-modified DNA by high-mobility-group proteins.
    Ohndorf UM; Rould MA; He Q; Pabo CO; Lippard SJ
    Nature; 1999 Jun; 399(6737):708-12. PubMed ID: 10385126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of nuclear factor kappaB proteins-platinated DNA interactions correlates with cytotoxic effectiveness of the platinum complexes.
    Brabec V; Kasparkova J; Kostrhunova H; Farrell NP
    Sci Rep; 2016 Aug; 6():28474. PubMed ID: 27574114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HMG-domain protein recognition of cisplatin 1,2-intrastrand d(GpG) cross-links in purine-rich sequence contexts.
    Cohen SM; Mikata Y; He Q; Lippard SJ
    Biochemistry; 2000 Sep; 39(38):11771-6. PubMed ID: 10995245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.